SCHEMBL5690583

SCHEMBL5690583

Cc1ccccc1OCCN(C)[C@H]1CC[C@H](c2ccc(OCc3ccccc3)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.42
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
KCNH2 Q12809 2/20 0.38
HRH3 Q9Y5N1 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAOB P27338 2/20 0.38
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
PRMT5 O14744 1/20 0.38
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5690585 1.00 KDM4E (0.44) KDM4EMRGPRX4NPC1MAPK1RAB9A
SCHEMBL5690074 0.89 KDM4E (0.49) KDM4EMRGPRX4KCNH2HRH3CYP3A4
SCHEMBL5690071 0.89 KDM4E (0.49) KDM4EMRGPRX4KCNH2HRH3CYP3A4
SCHEMBL5690106 0.88 KDM4E (0.46) KDM4EMRGPRX4KCNH2HRH3CYP3A4
SCHEMBL5689665 0.88 KDM4E (0.46) KDM4EMRGPRX4KCNH2HRH3CYP3A4
SCHEMBL5689670 0.88 KDM4E (0.46) KDM4EMRGPRX4KCNH2HRH3CYP3A4
SCHEMBL5689857 0.87 KDM4E (0.45) KDM4EMRGPRX4KCNH2HRH3CYP3A4
SCHEMBL5689775 0.87 KDM4E (0.45) KDM4EMRGPRX4KCNH2HRH3CYP3A4
SCHEMBL5689678 0.85 KDM4E (0.45) KDM4ESMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL5689673 0.85 KDM4E (0.45) KDM4ESMN1; SMN2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 EP disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed